Adhera Therapeutics, Inc. Announces Management Changes
July 13, 2020 at 07:58 am EDT
Share
On July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. appointed Andrew Kucharchuk to serve as a member of the Board of Directors, effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020. On July 10, 2020, the Board of Directors of the Company appointed Charles L. Rice to serve as a member of the Board of Directors, effective immediately, to fill the vacancy created by the resignation of Uli Hacksell, Ph.D. Mr. Rice, served as a member of the board of directors of OncBioMune Pharmaceuticals, Inc. from November 2015 until June 2020. On July 10, 2020, Uli Hacksell, Ph.D. submitted his resignation as a member of the Board of Directors of the Company, and from any other position or positions that he may hold as a director or officer of the Company or any of its subsidiaries (including any committees of the Board of Directors of the Company or any of its subsidiaries), in each case, effective immediately. On July 7, 2020, Rhonda Stanley, the Senior Vice President of Accounting of the Company, resigned as an officer of the Company, effective immediately.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
